Study Stopped
Zimmer Biomet is prioritizing specific products within its portfolio and has chosen not to extend the CE mark for the GTS stem under MDR requirements, leading to the premature termination of the GTS study in 2024.
A Prospective Study to Evaluate Long-term Clinical Outcomes of the GTS Cementless Femoral Stem
1 other identifier
interventional
303
0 countries
N/A
Brief Summary
This is a multicenter, non-controlled, prospective study. 303 subjects (GTS standard and lateralized) have been recruited. Study will be conducted in centers across Europe.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Sep 2012
Longer than P75 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2012
CompletedFirst Submitted
Initial submission to the registry
July 25, 2016
CompletedFirst Posted
Study publicly available on registry
August 2, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2020
CompletedResults Posted
Study results publicly available
December 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2025
CompletedAugust 10, 2026
July 1, 2026
7.7 years
July 25, 2016
July 7, 2023
July 16, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Mean Harris Hip Score
Harris Hip Score (HHS) tests will be carried out pre-operatively and at each follow-up period. The HHS covers four domains: pain (one item, 0-44 points), function and functional activities (seven items, 0-47 points), absence of deformity (one item, 0-4 points) and range of motion (one item, 0-5 points). To obtain a final score, the points are summed. The minimum and maximum values of the scale are 0-100, with a higher score indicating a better outcome. The outcome score can be categorized as Excellent: 90-100; Good: 80-90; Fair: 70-80; Poor: \< 70.
Pre-operatively, 3 months and 1, 2, 3, 5, 7, and 10 years post-operatively.
Secondary Outcomes (4)
Stability, Incidence of Radiolucencies Around the Prosthesis and Bone Remodeling
10 years post-surgery.
Patient Satisfaction
Pre-operatively, 3 months and 1, 2, 3, 5, 7, and 10 years post-surgery
Adverse Events/Complications
From surgery through the 10-year post-operative follow-up period.
Revision-Free Survivorship Through 10 Years
From implantation through 10 years post-operatively
Study Arms (1)
GTS cementless stem
OTHERTotal Hip arthroplasty with GTS cementless stem (standard and lateralized) with different cup and bearing options (metal-on-polyethylene or ceramic-on-polyethylene)
Interventions
Eligibility Criteria
You may qualify if:
- Primary osteoarthritis or secondary coxarthritis
- Inflammation of the hip: rheumatoid arthritis, etc.
- Femoral neck fracture
- Avascular necroses of the femoral head
- Sequelae from previous operations on the hip, osteotomies, etc.
- Congenital hip dysplasia
- years of age or older
- Subjects willing to return for follow-up evaluations
- Subjects who read, understood study information and provided an informed written consent (specific local regulatory requirements)
You may not qualify if:
- Absolute contraindications include:
- Local or systemic infections.
- Severe muscular, neurological or vascular deficiencies of the extremity involved
- Bone destruction or poor bone quality that is likely to affect implant stability(Paget's disease, osteoporosis, etc.)
- Concomitant disease likely to affect implant function
- Allergy to any of the components of the implant
- Patients weighing more than 110 kg
- Subjects unable to co-operate with and complete the study
- Dementia and/or inability to understand and follow instructions
- Neurological conditions affecting movement
- Patient over 18 under law supervision
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Zimmer Biometlead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Limitations and Caveats
The study was terminated prematurely, resulting in limited participant follow-up beyond 7 years and reduced long-term data availability.
Results Point of Contact
- Title
- Emilie Rohmer, Clinical Operations Assoc Director
- Organization
- Zimmer Biomet
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 25, 2016
First Posted
August 2, 2016
Study Start
September 1, 2012
Primary Completion
May 1, 2020
Study Completion
May 1, 2025
Last Updated
August 10, 2026
Results First Posted
December 1, 2023
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will not share